MD Anderson Cancer Center Uses Velos eResearch
Clinical Trial Management System to be Deployed throughout Enterprise
FREMONT, Calif., May 12, 2011 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions of all sizes, today announced an agreement with The University of Texas MD Anderson Cancer Center. The agreement calls for enterprise-wide installation of its flagship product, Velos eResearch. Installation is now underway with plans for production use in 2012.
MD Anderson initiates at least 1000 clinical studies each year and will deploy Velos eResearch. Currently, data is dispersed in many different applications and departments, requiring significant time and effort to build, submit, approve and complete a protocol.
About Velos
Velos is the trusted platform for clinical research and specialized medical records. Velos products are used by customers to manage all aspects of clinical research. Its products are used in medical specialties to manage distinctive, complex medical records. Velos delivers its products both for customer installation and as services on the Internet. Solutions from Velos include: Velos eResearch for clinical trial management, data capture, budgeting, and billing; Velos eIRB and Compliance solutions; Velos eSample for bio-specimen collection, tracking, and repository management; Velos eMaven for integration; and Velos specialty solutions in solid organ transplant, cell transplant, dialysis, and cardiology, among others. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com.
This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.
SOURCE Velos, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article